Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Random Match Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

NCT04643795
View directory record Official record
Conditions
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

NCT05147337
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2511, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

NCT04110145
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 26, 2026, 5:43 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

NCT02736409
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (OBS), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 26, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

NCT06776432
View directory record Official record
Conditions
Sleep Apnea
Interventions
Sivopixant, Placebo, Acetazolamide, SASS-001
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
La Jolla, California • Brandon, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 26, 2026, 5:43 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)

NCT07286032
View directory record Official record
Conditions
Patients With Chemotherapy-Induced Thrombocytopenia
Interventions
Hetrombopag Olamine, Hetrombopag Olamine; Hetrombopag Olamine Placebo
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Long Beach, California • Los Alamitos, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 5:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Single and Multiple Dose of HL-400

NCT06997484
View directory record Official record
Conditions
Parkinson Disease
Interventions
HL-400, Placebo
Drug
Lead sponsor
Highlightll Pharmaceutical (USA) LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Naldemedine

NCT01965652
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

NCT02932904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vortioxetine, Paroxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years
Enrollment
361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
15
States / cities
Encino, California • Long Beach, California • Torrance, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 26, 2026, 5:43 AM EDT
Withdrawn Not applicable Interventional

Digital Diabetes Prevention Program Study

NCT06137963
View directory record Official record
Conditions
PreDiabetes
Interventions
Transform10 Diabetes Prevention Program
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

NCT02443298
View directory record Official record
Conditions
Asthma
Interventions
placebo, risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

NCT05257265
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Centanafadine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

NCT03721107
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Blautix, Placebo
Biological · Other
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years to 70 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

NCT00090363
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054 15 mg, Placebo, ZD4054 10 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 26, 2026, 5:43 AM EDT
Recruiting Phase 2 Interventional

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

NCT06824064
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions
RBS2418, Placebo
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newark, Delaware • Kingwood, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT00889863
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
canakinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

NCT00621946
View directory record Official record
Conditions
Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

NCT04257929
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant oral tablets, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
13
States / cities
San Diego, California • San Ramon, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 26, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

NCT01430442
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 26, 2026, 5:43 AM EDT